Direct and rapid mass spectral fingerprinting of maternal urine for the detection of Down syndrome pregnancy

[1]  Ray K Iles,et al.  HILIC-MS-based shotgun metabolomic profiling of maternal urine at 9-23 weeks of gestation - establishing the baseline changes in the maternal metabolome. , 2015, Biomedical chromatography : BMC.

[2]  D. Trivedi,et al.  Do not just do it, do it right: urinary metabolomics--establishing clinically relevant baselines. , 2014, Biomedical chromatography : BMC.

[3]  A. Butch,et al.  Immunoextraction-tandem mass spectrometry method for measuring intact human chorionic gonadotropin, free β-subunit, and β-subunit core fragment in urine. , 2014, Clinical chemistry.

[4]  L. Cole,et al.  Direct Analysis of hCGβcf Glycosylation in Normal and Aberrant Pregnancy by Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry , 2014, International journal of molecular sciences.

[5]  J. Guibourdenche,et al.  hCG in screening for aneuploidy: a possible role for its glycoforms? , 2014, Placenta.

[6]  K. Nicolaides,et al.  Analysis of Cell-Free DNA in Maternal Blood in Screening for Aneuploidies: Meta-Analysis , 2014, Fetal Diagnosis and Therapy.

[7]  E. Diamandis,et al.  Deciphering the peptidome of urine from ovarian cancer patients and healthy controls , 2014, Clinical Proteomics.

[8]  H. Cuckle,et al.  Maternal cfDNA screening for Down syndrome – a cost sensitivity analysis , 2013, Prenatal diagnosis.

[9]  H. Cuckle,et al.  Non‐invasive prenatal testing for aneuploidy: current status and future prospects , 2013, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[10]  N. Avent,et al.  Non-Invasive Screening Tools for Down’s Syndrome: A Review , 2013, Diagnostics.

[11]  J. Visootsak,et al.  Noninvasive screening tools for Down syndrome: a review , 2013, International journal of women's health.

[12]  K. Lamnissou,et al.  MeDIP real‐time qPCR of maternal peripheral blood reliably identifies trisomy 21 , 2012, Prenatal diagnosis.

[13]  Aubrey Milunsky,et al.  Genetic Disorders and the Fetus: "Diagnosis, Prevention, And Treatment" , 2012 .

[14]  L. Cole,et al.  Hyperglycosylated hCG, hCGβ and Hyperglycosylated hCGβ: Interchangeable cancer promoters , 2012, Molecular and Cellular Endocrinology.

[15]  Stephen R Quake,et al.  Microfluidic digital PCR enables rapid prenatal diagnosis of fetal aneuploidy. , 2009, American journal of obstetrics and gynecology.

[16]  H. Neubert,et al.  Identification of Placental Transforming Growth Factor-β and Bikunin Metabolites as Contaminants of Pharmaceutical Human Chorionic Gonadotrophin Preparations by Proteomic Techniques* , 2005, Molecular & Cellular Proteomics.

[17]  A T Kicman,et al.  Identification of post-translational modifications resulting from LHbeta polymorphisms by matrix-assisted laser desorption time-of-flight mass spectrometric analysis of pituitary LHbeta core fragment. , 2003, Journal of molecular endocrinology.

[18]  Hendrik Neubert,et al.  Enhanced affinity capture MALDI-TOF MS: orientation of an immunoglobulin G using recombinant protein G. , 2002, Analytical chemistry.

[19]  A. Mantingh,et al.  Urinary hyperglycosylated hCG in first trimester screening for chromosomal abnormalities , 2000, Prenatal diagnosis.

[20]  A. Kicman,et al.  Determination of the glycoforms of human chorionic gonadotropin beta-core fragment by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. , 2000, Clinical chemistry.

[21]  N Seta,et al.  Protein glycosylation and diseases: blood and urinary oligosaccharides as markers for diagnosis and therapeutic monitoring. , 2000, Clinical chemistry.

[22]  I. Brewis.  Proteomics in reproductive research: the potential importance of proteomics to research in reproduction. , 1999, Human reproduction.

[23]  J. Canick,et al.  Collaborative study of maternal urine β ‐core human chorionic gonadotrophin screening for Down syndrome , 1999, Prenatal diagnosis.

[24]  R. Iles,et al.  Dimerization of urinary β‐core/hCFβcf: a cause of poor β‐core assay performance in Down syndrome screening studies , 1999 .

[25]  L. Cole,et al.  Urinary screening tests for fetal Down syndrome: I. Fresh β‐core fragment , 1999 .

[26]  L. Cole,et al.  Urinary screening tests for fetal Down syndrome: II. Hyperglycosylated hCG , 1999, Prenatal diagnosis.

[27]  J. Canick,et al.  Urinary analyte screening: a noninvasive detection method for Down syndrome? , 1999, Molecular medicine today.

[28]  L. Cole,et al.  Urinary screening tests for fetal Down syndrome: I. Fresh beta-core fragment. , 1999, Prenatal diagnosis.

[29]  R. Iles,et al.  Dimerization of urinary beta-core/hCFbetacf: a cause of poor beta-core assay performance in Down syndrome screening studies. , 1999, Prenatal diagnosis.

[30]  L. Cole,et al.  Dissociation of Human Chorionic Gonadotrophin into its Free Subunits is Dependent on Naturally Occurring Molecular Structural Variation, Sample Matrix and Storage Conditions , 1998, Annals of clinical biochemistry.

[31]  H. Cuckle,et al.  Measures of urine concentration in maternal urine screening for Down syndrome , 1998, Prenatal diagnosis.

[32]  L. Cole,et al.  Hyperglycosylated hcg, a potential alternative to hcg in Down syndrome screening , 1998, Prenatal diagnosis.

[33]  L. Cole,et al.  Combining β‐core fragment and total oestriol measurements to test for Down syndrome pregnancies , 1997 .

[34]  L. Cole,et al.  Combining beta-core fragment and total oestriol measurements to test for Down syndrome pregnancies. , 1997, Prenatal diagnosis.

[35]  J. Canick,et al.  Detection of β-core fragment in second trimester Down's syndrome pregnancies , 1996 .

[36]  R. Iles.  Urinary analysis for Down's syndrome: is the measurement of urinary beta-core the future of biochemical screening for Down's syndrome. , 1996, Early human development.

[37]  J. Canick,et al.  LETTER TO THE EDITOR. URINARY β‐CORE‐hCG SCREENING IN THE FIRST TRIMESTER , 1996 .

[38]  T. Chard,et al.  The temporary anatomical structures prominent in the first trimester may be fulfilling exchange functions assigned to the placenta in the second and third trimester. , 1996, Human reproduction.

[39]  H. Cuckle,et al.  Urinary multiple marker screening for down's syndrome , 1995, Prenatal diagnosis.

[40]  H. Cuckle,et al.  Urinary β‐core human chorionic gonadotrophin: A new approach to Down's syndrome screening , 1994, Prenatal diagnosis.

[41]  T. Hamamoto,et al.  Structures of the asparagine-linked sugar chains of human chorionic gonadotropin produced in choriocarcinoma. Appearance of triantennary sugar chains and unique biantennary sugar chains. , 1983, The Journal of biological chemistry.

[42]  Y. Yoshimoto,et al.  Glycosylation, a variable in the production of hCG by cancers. , 1979, The American journal of medicine.